Skip to content

News & calendar

news: as of 2026-10-09
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Wed · 15 Jul

funding

06:08
Google News: Shell plc

Nigeria offers Shell bigger tax incentive to fast-track $20 billion oil investment

Nigeria offered Shell a larger tax incentive to accelerate a $20 billion oil investment.

Markets open original ↗

earnings

05:01
Google News: DocMorris AG

DocMorris reports strong revenue growth of 15% in the second quarter; Rx grows by 46% and Digital Services by 80%

DocMorris reported 15% revenue growth in Q2, with Rx up 46% and Digital Services up 80%.

Markets open original ↗

regulation

03:45
Google News: Regeneron Pharmaceuticals, Inc.

Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu

Regeneron received FDA Orphan Drug Designation for Dupilumab.

Markets open original ↗

partnership

00:45
Google News: Voyager Technologies

Voyager closes Astrobotic deal following new NASA lunar contracts

Voyager Technologies closed its Astrobotic acquisition following new NASA lunar contracts.

Markets open original ↗

regulation

00:00
GlobeNewswire

Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management in the EU

The European Commission approved Novo Nordisk's oral Wegovy (once-daily oral semaglutide 25 mg), the first oral GLP-1 approved for weight management in the EU; the EC also approved a single, ready-to-use Wegovy 7.2 mg pen for a higher dose.

Markets open original ↗

The wire

everything that arrived · 7 days